Condition: Gastric (Stomach) Cancer · GastroEsophageal Cancer · Pancreatic Ductal Adenocarcinoma (mPDAC) · Sponsor: Dong-A ST Co., Ltd.
The goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expressing (CLDN18.2+) GC/GEJ and advanced CLDN18.2+ PDAC. Participants will receive the assigned dose once every three weeks and, according to the study procedures, will undergo tumor assessments as well as safety assessments, PK evaluations, and ADA testing.
This description comes directly from the study's public registry record.
Jiwon Shin · 82-2-920-8768 · jiwon_shin@donga.co.kr
Always discuss trial participation with your own doctor first.
| CHA University Bundang Medical Center | Seongnam, Bundang, South Korea | Recruiting |
| Seoul National University Bundang Hospital | Seongnam, Bundang, South Korea | Recruiting |
| Severance Hospital | Seoul, Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07481357